Pharmaceuticals

Asia Leaders

Vasant Narasimhan Remade Novartis as a Pure-Play Medicines Company. New Launches Must Outrun the Patent Cycle

Novartis is strategically simpler but commercially exposed to patent erosion. Vasant Narasimhan's next test is making new medicines grow faster than older franchises decline.

Asia Leaders

Sun Pharma’s Dilip Shanghvi Keeps Choosing Specialty Over Spectacle

A FigureAsia examination of how Dilip Shanghvi is positioning Sun Pharma for the next phase of pharmaceuticals.

Asia Leaders

Reshma Kewalramani Is Betting Vertex’s Balance Sheet on a US$10 Billion Endocrine Expansion

Vertex’s agreement to buy Crinetics for about US$10 billion is Reshma Kewalramani’s largest strategic wager. The deal could accelerate non-cystic-fibrosis revenue, but its financing, integration and peak-sales assumptions now demand unusually close scrutiny.

Asia Leaders

Vasant Narasimhan Is Funding Novartis’s Next Growth Cycle with Debt, Deals and China Capacity

Vasant Narasimhan has committed Novartis to a rapid sequence of acquisitions and Chinese investment while net debt rises. The strategy could rebuild growth across RNA medicine, oncology and radioligand therapy, but execution now matters more than portfolio rhetoric.

Asia Leaders

Christophe Weber Made Takeda Global and Now Must Make the Portfolio Pay

A FigureAsia examination of how Christophe Weber is positioning Takeda for the next phase of pharmaceuticals.

Asia Leaders

Pankaj Patel Wants Zydus to Be Known for More Than Affordable Medicines

A FigureAsia examination of how Pankaj Patel is positioning Zydus for the next phase of pharmaceuticals.

Asia Leaders

Vasant Narasimhan Narrowed Novartis to Innovative Medicines. The Portfolio Must Now Outrun Its Patent Losses

Novartis is strategically cleaner but its leading medicines face inevitable erosion. Vasant Narasimhan’s next task is converting a promising pipeline into dependable growth.